Nintedanib

Nintedanib, the active ingredient in Nintedanib, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients. It is administered orally and works by targeting multiple growth factor receptors involved in fibrotic processes.

GNH USA supplies Nintedanib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable access to this antifibrotic therapy for patients in need.

Nintedanib is used to address fibrotic and oncologic conditions by inhibiting key pathways involved in disease progression.

Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening of fibrosis. Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth.

Nintedanib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling sick. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increase in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: marked enzyme rise or hepatitis. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Gastrointestinal perforation: rare tearing of the intestinal wall.

When prescribing Nintedanib, clinicians should consider several safety measures to minimize risk. - Monitor liver function: perform baseline and periodic ALT/AST testing. - Assess bleeding risk: avoid in patients with active hemorrhage or on anticoagulants. - Evaluate cardiovascular status: caution in patients with history of arterial thromboembolism. - Watch for gastrointestinal symptoms: manage diarrhea and nausea promptly. - Pregnancy and lactation: contraindicated or use only if benefits outweigh risks (category unknown). - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - P-glycoprotein substrates (e.g., digoxin): potential altered absorption. - CYP3A4 inducers (e.g., rifampicin): may reduce Nintedanib effectiveness.